Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 31.68
(1.57%)
USD 31.68
(1.57%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 41.52 Million USD | -90.52% |
| 2022 | 437.96 Million USD | 4.14% |
| 2021 | 420.55 Million USD | 7.74% |
| 2020 | 390.33 Million USD | 3.92% |
| 2019 | 375.61 Million USD | 14.01% |
| 2018 | 329.46 Million USD | 1141.33% |
| 2017 | 26.54 Million USD | 537.24% |
| 2016 | 4.16 Million USD | -42.06% |
| 2015 | 7.18 Million USD | -73.32% |
| 2014 | 26.94 Million USD | -21.65% |
| 2013 | 34.39 Million USD | 50.21% |
| 2012 | 22.89 Million USD | -22.35% |
| 2011 | 29.48 Million USD | -60.69% |
| 2010 | 75 Million USD | 0.0% |
| 2009 | 75 Million USD | 0.0% |
| 2008 | 75 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 39.97 Million USD | -5.1% |
| 2024 Q3 | 28.92 Million USD | -4.56% |
| 2024 Q1 | 42.12 Million USD | 1.44% |
| 2023 Q2 | 42.19 Million USD | -91.84% |
| 2023 Q1 | 517.37 Million USD | 18.13% |
| 2023 Q4 | 41.52 Million USD | -1.88% |
| 2023 FY | 41.52 Million USD | -90.52% |
| 2023 Q3 | 42.32 Million USD | 0.3% |
| 2022 Q4 | 437.96 Million USD | 0.11% |
| 2022 FY | 437.96 Million USD | 4.14% |
| 2022 Q1 | 446.41 Million USD | 6.15% |
| 2022 Q2 | 445.02 Million USD | -0.31% |
| 2022 Q3 | 437.46 Million USD | -1.7% |
| 2021 Q2 | 406.52 Million USD | 3.03% |
| 2021 Q4 | 420.55 Million USD | 2.06% |
| 2021 Q1 | 394.57 Million USD | 1.09% |
| 2021 FY | 420.55 Million USD | 7.74% |
| 2021 Q3 | 412.04 Million USD | 1.36% |
| 2020 Q3 | 413.68 Million USD | 1.0% |
| 2020 Q1 | 380.03 Million USD | 1.18% |
| 2020 Q2 | 409.6 Million USD | 7.78% |
| 2020 FY | 390.33 Million USD | 3.92% |
| 2020 Q4 | 390.33 Million USD | -5.65% |
| 2019 Q4 | 375.61 Million USD | 1.95% |
| 2019 FY | 375.61 Million USD | 14.01% |
| 2019 Q1 | 361.13 Million USD | 9.61% |
| 2019 Q2 | 364.74 Million USD | 1.0% |
| 2019 Q3 | 368.41 Million USD | 1.01% |
| 2018 Q1 | 318.22 Million USD | 1098.99% |
| 2018 Q4 | 329.46 Million USD | 1.17% |
| 2018 FY | 329.46 Million USD | 1141.33% |
| 2018 Q3 | 325.66 Million USD | 1.16% |
| 2018 Q2 | 321.92 Million USD | 1.16% |
| 2017 Q3 | 27.95 Million USD | 1799.18% |
| 2017 FY | 26.54 Million USD | 537.24% |
| 2017 Q1 | 3.31 Million USD | -20.53% |
| 2017 Q2 | 1.47 Million USD | -55.53% |
| 2017 Q4 | 26.54 Million USD | -5.06% |
| 2016 FY | 4.16 Million USD | -42.06% |
| 2016 Q4 | 4.16 Million USD | -27.84% |
| 2016 Q3 | 5.77 Million USD | 1.28% |
| 2016 Q2 | 5.69 Million USD | 1.28% |
| 2016 Q1 | 5.62 Million USD | -21.73% |
| 2015 Q4 | 7.18 Million USD | -10.89% |
| 2015 FY | 7.18 Million USD | -73.32% |
| 2015 Q1 | 11.7 Million USD | -56.55% |
| 2015 Q2 | 8.76 Million USD | -25.16% |
| 2015 Q3 | 8.06 Million USD | -7.92% |
| 2014 Q1 | 28.35 Million USD | -17.55% |
| 2014 FY | 26.94 Million USD | -21.65% |
| 2014 Q4 | 26.94 Million USD | 1.7% |
| 2014 Q3 | 26.49 Million USD | -7.58% |
| 2014 Q2 | 28.67 Million USD | 1.1% |
| 2013 Q4 | 34.39 Million USD | -42.85% |
| 2013 FY | 34.39 Million USD | 50.21% |
| 2013 Q1 | 20.11 Million USD | -12.16% |
| 2013 Q2 | 59.1 Million USD | 193.85% |
| 2013 Q3 | 60.17 Million USD | 1.82% |
| 2012 Q1 | 29.09 Million USD | -1.32% |
| 2012 Q2 | 27.8 Million USD | -4.43% |
| 2012 FY | 22.89 Million USD | -22.35% |
| 2012 Q4 | 22.89 Million USD | -10.58% |
| 2012 Q3 | 25.6 Million USD | -7.92% |
| 2011 Q3 | 89.51 Million USD | 0.0% |
| 2011 Q4 | 29.48 Million USD | -67.06% |
| 2011 FY | 29.48 Million USD | -60.69% |
| 2010 FY | 75 Million USD | 0.0% |
| 2010 Q3 | 75 Million USD | 0.0% |
| 2010 Q4 | 75 Million USD | 0.0% |
| 2009 FY | 75 Million USD | 0.0% |
| 2009 Q4 | 75 Million USD | 0.0% |
| 2008 FY | 75 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.881% |
| Dynavax Technologies Corporation | 256.91 Million USD | 83.836% |
| Illumina, Inc. | 2.26 Billion USD | 98.164% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.708% |
| Biogen Inc. | 7.33 Billion USD | 99.434% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -4052.7% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 98.084% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 97.027% |
| Waters Corporation | 2.35 Billion USD | 98.237% |
| Perrigo Company plc | 4.07 Billion USD | 98.981% |
| uniQure N.V. | 138.4 Million USD | 69.997% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 27.13% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 90.669% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 28.243% |
| bluebird bio, Inc. | 330.32 Million USD | 87.428% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 3.799% |
| Imunon, Inc. | 1.13 Million USD | -3544.98% |
| Myriad Genetics, Inc. | 145 Million USD | 71.361% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 90.306% |
| Nektar Therapeutics | 230.4 Million USD | 81.976% |
| Editas Medicine, Inc. | 36.53 Million USD | -13.66% |
| Verastem, Inc. | 41.55 Million USD | 0.072% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.565% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -98.844% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 76.1% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -53.861% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 96.338% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -8.983% |
| Evolus, Inc. | 126.54 Million USD | 67.184% |
| Adicet Bio, Inc. | 17.7 Million USD | -134.576% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1250.911% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.464% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 92.323% |
| FibroGen, Inc. | 170.45 Million USD | 75.638% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.482% |
| OPKO Health, Inc. | 326.56 Million USD | 87.284% |
| Homology Medicines, Inc. | 44.05 Million USD | 5.736% |
| Geron Corporation | 85.89 Million USD | 51.656% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 98.268% |
| Exelixis, Inc. | 189.94 Million USD | 78.137% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -3195.794% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 63.998% |
| Zoetis Inc. | 6.8 Billion USD | 99.39% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 77.718% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -843.367% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 94.863% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -14.327% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 97.143% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -27401.325% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.23% |
| Blueprint Medicines Corporation | 774.12 Million USD | 94.636% |
| Insmed Incorporated | 1.2 Billion USD | 96.551% |
| TG Therapeutics, Inc. | 110.79 Million USD | 62.519% |
| Incyte Corporation | 38.28 Million USD | -8.462% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 95.268% |